These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 35732328)

  • 41. CRISPR-Cas9 knockout screen identifies novel treatment targets in childhood high-grade glioma.
    Wenger A; Karlsson I; Kling T; Carén H
    Clin Epigenetics; 2023 May; 15(1):80. PubMed ID: 37161535
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Receptor tyrosine kinase (RTK) targeting in pediatric high-grade glioma and diffuse midline glioma: Pre-clinical models and precision medicine.
    Schwark K; Messinger D; Cummings JR; Bradin J; Kawakibi A; Babila CM; Lyons S; Ji S; Cartaxo RT; Kong S; Cantor E; Koschmann C; Yadav VN
    Front Oncol; 2022; 12():922928. PubMed ID: 35978801
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Current and future directions for Phase II trials in high-grade glioma.
    Alexander BM; Lee EQ; Reardon DA; Wen PY
    Expert Rev Neurother; 2013 Apr; 13(4):369-87. PubMed ID: 23545053
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Co-occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma.
    Pagès M; Beccaria K; Boddaert N; Saffroy R; Besnard A; Castel D; Fina F; Barets D; Barret E; Lacroix L; Bielle F; Andreiuolo F; Tauziède-Espariat A; Figarella-Branger D; Puget S; Grill J; Chrétien F; Varlet P
    Brain Pathol; 2018 Jan; 28(1):103-111. PubMed ID: 27984673
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dual HDAC and PI3K Inhibition Abrogates NFκB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas.
    Pal S; Kozono D; Yang X; Fendler W; Fitts W; Ni J; Alberta JA; Zhao J; Liu KX; Bian J; Truffaux N; Weiss WA; Resnick AC; Bandopadhayay P; Ligon KL; DuBois SG; Mueller S; Chowdhury D; Haas-Kogan DA
    Cancer Res; 2018 Jul; 78(14):4007-4021. PubMed ID: 29760046
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel insights on genetics and epigenetics as clinical targets for paediatric astrocytoma.
    Johns DA; Williams RJ; Smith CM; Nadaminti PP; Samarasinghe RM
    Clin Transl Med; 2024 Feb; 14(2):e1560. PubMed ID: 38299304
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular pathogenesis and therapeutic implications in pediatric high-grade gliomas.
    Juratli TA; Qin N; Cahill DP; Filbin MG
    Pharmacol Ther; 2018 Feb; 182():70-79. PubMed ID: 28830841
    [TBL] [Abstract][Full Text] [Related]  

  • 48. H3.3
    Pathania M; De Jay N; Maestro N; Harutyunyan AS; Nitarska J; Pahlavan P; Henderson S; Mikael LG; Richard-Londt A; Zhang Y; Costa JR; Hébert S; Khazaei S; Ibrahim NS; Herrero J; Riccio A; Albrecht S; Ketteler R; Brandner S; Kleinman CL; Jabado N; Salomoni P
    Cancer Cell; 2017 Nov; 32(5):684-700.e9. PubMed ID: 29107533
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Pediatric Hemispheric Glioma].
    Nakano Y; Ichimura K; Sakamoto H
    No Shinkei Geka; 2022 Jan; 50(1):122-131. PubMed ID: 35169092
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Compendium of Syngeneic, Transplantable Pediatric High-Grade Glioma Models Reveals Subtype-Specific Therapeutic Vulnerabilities.
    McNicholas M; De Cola A; Bashardanesh Z; Foss A; Lloyd CB; Hébert S; Faury D; Andrade AF; Jabado N; Kleinman CL; Pathania M
    Cancer Discov; 2023 Jul; 13(7):1592-1615. PubMed ID: 37011011
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
    Chen R; Cohen AL; Colman H
    Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Celastrol-induced degradation of FANCD2 sensitizes pediatric high-grade gliomas to the DNA-crosslinking agent carboplatin.
    Metselaar DS; Meel MH; Benedict B; Waranecki P; Koster J; Kaspers GJL; Hulleman E
    EBioMedicine; 2019 Dec; 50():81-92. PubMed ID: 31735550
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Unbiased Proteomic and Phosphoproteomic Analysis Identifies Response Signatures and Novel Susceptibilities After Combined MEK and mTOR Inhibition in BRAF
    Maxwell MJ; Arnold A; Sweeney H; Chen L; Lih TM; Schnaubelt M; Eberhart CG; Rubens JA; Zhang H; Clark DJ; Raabe EH
    Mol Cell Proteomics; 2021; 20():100123. PubMed ID: 34298159
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tumor location, but not H3.3K27M, significantly influences the blood-brain-barrier permeability in a genetic mouse model of pediatric high-grade glioma.
    Subashi E; Cordero FJ; Halvorson KG; Qi Y; Nouls JC; Becher OJ; Johnson GA
    J Neurooncol; 2016 Jan; 126(2):243-51. PubMed ID: 26511492
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genomic profiling and prognostic factors of H3 K27M-mutant spinal cord diffuse glioma.
    Chai RC; Yan H; An SY; Pang B; Chen HY; Mu QH; Zhang KN; Zhang YW; Liu YQ; Liu X; Zhao Z; Jiang T; Wang YZ; Jia WQ
    Brain Pathol; 2023 Jul; 33(4):e13153. PubMed ID: 36751054
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gliomas in children and adolescents: investigation of molecular alterations with a potential prognostic and therapeutic impact.
    Cabral de Carvalho Corrêa D; Tesser-Gamba F; Dias Oliveira I; Saba da Silva N; Capellano AM; de Seixas Alves MT; Dastoli PA; Cavalheiro S; Caminada de Toledo SR
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):107-119. PubMed ID: 34626238
    [TBL] [Abstract][Full Text] [Related]  

  • 58. ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma.
    Arrillaga-Romany I; Lassman A; McGovern SL; Mueller S; Nabors B; van den Bent M; Vogelbaum MA; Allen JE; Melemed AS; Tarapore RS; Wen PY; Cloughesy T
    Neuro Oncol; 2024 May; 26(Supplement_2):S173-S181. PubMed ID: 38445964
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Type 1 IGF receptor associates with adverse outcome and cellular radioresistance in paediatric high-grade glioma.
    Simpson AD; Soo YWJ; Rieunier G; Aleksic T; Ansorge O; Jones C; Macaulay VM
    Br J Cancer; 2020 Mar; 122(5):624-629. PubMed ID: 31857716
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Platelet-derived growth factor beta is a potent inflammatory driver in paediatric high-grade glioma.
    Ross JL; Chen Z; Herting CJ; Grabovska Y; Szulzewsky F; Puigdelloses M; Monterroza L; Switchenko J; Wadhwani NR; Cimino PJ; Mackay A; Jones C; Read RD; MacDonald TJ; Schniederjan M; Becher OJ; Hambardzumyan D
    Brain; 2021 Feb; 144(1):53-69. PubMed ID: 33300045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.